Sage Therapeutics has rejected the unsolicited acquisition offer it received earlier this month from longtime partner Biogen ...

Sage Therapeutics has rejected a buyout bid from partner Biogen and launched a review of strategic alternatives. Sage on Monday said its board determined that Biogen's $7.22-a-share proposal ...

Alzheimer's disease progression does not stop after plaque clearance; ongoing treatment with LEQEMBI can slow disease progression and prolong the benefits of therapy TOKYO and CAMBRIDGE, Mass., Jan.

Zurzuvae was not approved as a treatment for major depressive disorder, as the two Cambridge drugmakers had been hoping. Biogen and Sage decided last year not pursue further development of the ...

CAMBRIDGE, Mass., January 10, 2025--(BUSINESS WIRE)--Sage Therapeutics, Inc. (Nasdaq: SAGE) ("The Company"), today confirmed that Biogen Inc. (Nasdaq: BIIB) ("Biogen ...

The proposal values Sage at around $442 million. A yearslong partner of neuroscience player Sage, Biogen already owns 10.2% of the Cambridge, Massachusetts-based biotech, according to the filing.

The Cambridge, Massachusetts-based biotech added that its board of directors, along with its independent financial and legal advisors, will evaluate Biogen’s (NASDAQ:BIIB) bid and decide on the ...

Police in Cambridgeshire regularly issue CCTV pictures of people they want to ... to in connection with a number of thefts from shops in Cambridge. Anyone with information regarding either of ...

Biogen currently owns a 10.2% stake in SAGE, and its offer price implies a ~30% premium to the company’s closing price on Friday. More on Biogen, Sage Therapeutics, etc. Biogen Holds On, But ...

Jane Grogan, Ph.D., took over Biogen’s research department in the wake of large-scale layoffs. Now, a little more than a year later, she’s making cuts of her own. The neuro-focused biotech is ...

This evening and tonight will continue to be dry with largely clear skies throughout, and just the odd light patch of cloud in places. Wednesday Tomorrow will see a dry and bright start. Into the ...

Fresh off a reorganization, Biogen’s research leader Jane Grogan says the biotech has to 'look outside the walls of the ...